An Evaluation of the Impact of PD-1 Pathway Blockade on Reproductive Safety of Therapeutic PD-1 Inhibitors

Birth Defects Research Part B - Developmental and Reproductive Toxicology

Volumn 107, Issue 2, 2016, Pages 108-119

  Poulet, Frederique M ^a   Wolf, Jayanthi J ^a   Herzyk, Danuta J ^a   Degeorge, Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Alternative models; Biopharmaceuticals; Fetus; PD 1 PD L1; Pregnancy; Reproductive toxicity; Risk assessment

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR INHIBITOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELLULAR IMMUNITY; CLINICAL ASSESSMENT; DEVELOPMENTAL TOXICITY; DISEASE MARKER; DRUG EFFECT; DRUG SAFETY; HUMAN; IMMUNOLOGICAL TOLERANCE; MATERNAL BLOOD; MONOTHERAPY; NEOPLASM; NONHUMAN; PREGNANT WOMAN; PRIORITY JOURNAL; REPRODUCTION; REPRODUCTIVE TOXICITY; REVIEW; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SYNCYTIOTROPHOBLAST; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; IMMUNOTHERAPY; METABOLISM; MOUSE; NEOPLASMS; PLACENTA; PRECLINICAL STUDY; PREGNANCY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASMS; PLACENTA; PREGNANCY; REPRODUCTION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84963625982     PISSN: 15429733     EISSN: 15429741     Source Type: Journal    
DOI: 10.1002/bdrb.21176     Document Type: Review

References (83)

1. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T. 1996. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8:765-772.
2. Aluvihare VR, Kallikourdis M, Betz AG. 2004. Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 5:266-271.
3. Baban B, Chandler P, McCool D, Marshall B, Munn DH, Mellor AL. 2004. Indoleamine 2, 3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol 61:67-77.
4. Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT, Festing MF, Fisher EM. 2000. Genealogies of mouse inbred strains. Nat Genet 24:23-25. Available at: www.informatics.jax.org/mgihome/genealogy. Accessed August 21, 2015.
5. Bilinski MJ, Thorne JG, Oh MJ, Leonard S, Murrant C, Tayade C, Croy BA. 2008. Uterine NK cells in murine pregnancy. Reprod Biomed Online 16:218-226.
6. Blank C, Mackensen A. 2007. Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 56:739-745.
7. Brown JA, Dorfman DM, Ma F-R, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ. 2003. Blockade of programmed death-1 ligands on dendritic cells enhances T-cell activation and cytokine production. J Immunol 170:1257-1266.
8. Cai G, Karni A, Oliveira EM, Weiner HL, Hafler DA, Freeman GJ. 2004. PD-1 ligands, negative regulators for activations of naïve, memory, and recently activated human CD4+ T-cells. Cell Immunol 230:89-98.
9. Cao W, Brenner CA, Alikani M, Cohen J, Warner CM. 1999. Search for a human homologue of the mouse Ped gene. Mol Hum Reprod 5:541-547.
10. Chellman GJ, Bussiere JL, Makori N, Martin PL, Ooshima Y, Weinbauer GF. 2009. Developmental and reproductive toxicology studies in nonhuman primates. Birth Defects Res (Part B) 86:446-462.
11. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. 2004. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T-cell stimulation, but only receptor ligation prevents T-cell activation. J Immunol 173:945-954.
12. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. 2008. The indoleamine 2, 3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol 181:5396-5404.
13. Cheng S-B, Sharma S. 2015. Interleukin-10: a pleiotropic regulator in pregnancy. Am J Reprod Immunol 73:487-500.
14. D'Addio F, Riella LV, Mfarrej BG, Chabtini L, Adams LT, Yeung M, Yagita H, Azuma M, Sayegh MH, Guleria I. 2011. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol 187:4530-4541.
15. DeSesso JM, Williams AL, Ahuja A, Bowman CJ, Hurtt ME. 2012. The placenta, transfer of immunoglobulins, and safety assessment of biopharmaceuticals in pregnancy. Crit Rev Toxicol 42:185-210.
16. Disis ML. 2010. Immune regulation of cancer. J Clin Oncol 28:4531-4538.
17. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23:2346-2357.
18. Erlebacher A. 2013. Mechanisms of T cell tolerance towards the allogeneic fetus. Nat Immunol 13:23-33.
19. Erlebacher A, Vencato D, Price KA, Zhang D, Glimcher LH. 2007. Constraints in antigen presentation severely restrict T cell recognition of the allogeneic fetus. J Clin Invest 117:1399-1411.
20. Fernandez N, Cooper J, Sprinks M, AbdElrahman M, Fiszer D, Kurpisz M, Dealtry G. 1999. A critical review of the role of the major histocompatibility complex in fertilization, preimplantation development and feto-maternal interactions. Hum Reprod Update 5:234-248.
21. FDA. Pharmacology review for OPDIVO (nivolumab). Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000TOC.cfm published January 21, 2015. Accessed January 23, 2015.
22. Francisco LM, Sage PT, Sharpe AH. 2010. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 236:219-242.
23. Galon J, Costes A, Snchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus m, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc P-H, Trajanoski Z, Fridman W-H, Pages F. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960-1964.
24. Georgiades P, Ferguson-Smith AC, Burton GJ. 2002. Comparative developmental anatomy of the murine and human definitive placentae. Placenta 23:3-19.
25. Greenwald RJ, Freeman GJ, Sharpe AH. 2005. The B7 family revisited. Annu Rev Immunol 23:515-548.
26. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA. 2014. PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors. J Clin Invest 124:2246-2259.
27. Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, Noelle RJ, Coyle A, Mellor AL, Khoury SJ, Sayegh MH. 2005. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 202:231-237.
28. Guleria I, Sayegh MH. 2007. Maternal acceptance of the fetus: true human tolerance. J Immunol 178:3345-3351.
29. Habicht A, Dada S, Jurewicz M, Fife BT, Yagita H, Azuma M, Sayegh MH, Guleria I. 2007. A link between PDL1 and T regulatory cells in fetomaternal tolerance. J Immunol 179:5211-5219.
30. Hendrie TA, Peterson PE, Short JJ, Tarantal AF, Rothgarn E, Hendrie MI, Hendrickx AG. 1996. Frequency of prenatal loss in a macaque breeding colony. Am J Primatol 40:41-53.
31. Holmes CH, Simpson KL. 1992. Complement and pregnancy: new insights into the immunobiology of the fetomaternal relationship. Baillieres Clin Obstet Gynecol 6:439-460.
32. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth, A, Gnjatic S, Thompson JA, Yee C. 2008. Treatment of metastatic melanoma with autologous CD4+ T-cells against NY-ESO-1. N Engl J Med 358:2698-2703.
33. ICH S5(R2). 2005. Detection of toxicity to reproduction for medicinal products & toxicity to male fertility. Available at: www.ich.org. Accessed November 9, 2000.
34. ICH S6(R1). 2011. Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Parent guideline dated 16 July 1997. Available at: www.ich.org. Accessed June 12, 2011.
35. ICH S9. 2010. Nonclinical evaluation for anticancer pharmaceuticals. Available at: www.ich.org. Accessed June 25, 2015.
36. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. 2002. Involvment of PDL1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293-12297.
37. Kane SV, Acquah LA. 2009. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 104:228-233.
38. Kaufman KA, Bowen JA, Tsai AF, Bluestone JA, Hunt JS, Ober C. 1999. The CTLA-4 gene is expressed in placental fibroblasts. Mol Hum Reprod 5:84-87.
39. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH. 2006. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 203:883-895.
40. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. 2008. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677-704.
41. Korman A, Chen B, Wang C, Wu L, Cardarelli J, Selby M. 2007. Activity of anti-PD-1 in murine tumor models: Role of 'Host' PD-L1 and synergistic effect of anti-PD-1 and anti-CTLA-4. J Immunol 178:abstr. 48.37.
42. Le Bouteiller P, Solier C, Proll J, Aguerre-Girr M, Fournel S, Lenfant F. 1999. The major histocompatibility complex in pregnancy: part II. Placental HLA-G protein expression in vivo: where and what for? Hum Reprod Update 5:223-233.
43. Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. 1996. Evolution of maternal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 36:248-255.
44. Martin PL, Breslin W, Rocca M, Wright D, Cavagnaro J. 2009. Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals. Birth Def Res (part B) 86:176-203.
45. Martin PL, Weinbauer GF. 2010. Developmental toxicity testing of biopharmaceuticals in nonhuman primates: previous experience and future directions. Int J Toxicol 29:552-568.
46. Mellor AL, Munn DH. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nature Rev Immunol 4:762-774.
47. Miwa N, Hayakawa S, Miyazaki S, Myojo S, Sasaki Y, Sakai M, Takikawa O, Saito S. 2005. IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-γ increase in normal pregnancy but decrease in spontaneous abortion. Mol Hum Reprod 11:865-870.
48. Mor G, Gutierrez LS, Eliza M, Kahyaoglu F, Arici A. 1998. Fas-Fas ligand system-induced apoptosis in human placenta and gestational trophoblastic disease. Am J Reprod Immunol 40:89-94.
49. Morse HC, III. 1981. The laboratory mouse: a historical perspective. In: Foster HL, Small JD, Fox JG, editors. The mouse in biomedical research. Volume 1. History, genetics and wild mice. New York, NY: Academic Press. p 1-16.
50. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. 1999. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11:141-151.
51. Nishimura H, Honjo T, Minato N. 2000. Facilitation of beta selection and modification of positive selection in the thymus of PD-1-deficient mice. J Exp Med 191:891-898.
52. Nishimura H, Okazaki T, Tanaka Y, Nakatani K, Hara M, Matsumori A, Sasayama S, Mizoguchi A, Hiai H, Minato N, Honjo T. 2001. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291:319-322.
53. Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro, H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y. 2007. Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 13:2151-2157.
54. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T. 2001. PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci USA 98:13866-13871.
55. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc P-H, Trajanoski Z, Fridman W-H, Galon J. 2005. Effector memory T cells, early metastasis, and survival `ectal cancer. N Eng J Med 353:2654-2666.
56. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL. 2005. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 25:9543-9553.
57. Petroff MG. 2011. Review: fetal antigens-identity, origins, and influences on the maternal immune system. Placenta 25:S176-S181.
58. Pentsuk N, van der Laan JW. 2009. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. Birth Defects Res (Part B) 86:328-344.
59. Price KD, Rao GK. 2013. Biological therapies for cancer. In: Plitnick LM, Herzyk DJ, editors. Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics. New York, NY: Elsevier Inc. p 328-335.
60. Qiu Q, Yang M, Tsang BK, Gruslin A. 2005. Fas ligand expression by maternal decidual cells is negatively correlated with the abundance of leukocytes present at the maternal-fetal interface. J Reprod Immunol 65:121-132.
61. Rapacz-Leonard A, Dabrowska M, Janowski T. 2014. Major histocompatibility complex I mediates immunological tolerance of the trophoblast during pregnancy and may mediate rejection during parturition. Mediators Inflamm 2014:ID579279. Available at: http://dx.doi.org/10.1155/2014/579279. Accessed October 19, 2015.
62. Riley JL. 2009. PD-1 signaling in primary T-cells. Immunol Rev 229:114-125.
63. Rodrigues MN, Favaron PO, Dombrowski JG, de Souza RM, Miglino MA. 2013. Role of natural killer (NK) cells during pregnancy: a review. Open J Anim Sci 3:138-144. Available at: http://dx.doi.org/10.4236/ojas.2013.32021. Accessed October 20, 2015.
64. Sargent IL, Borzychowski AM, Redman CWG. 2006. NK cells and human pregnancy. An inflammatory view. Trends Immunol 27:399-404.
65. Schjenken JE, Tolosa JM, Paul JW, Clifton VL, Smith R. 2012. Mechanisms of maternal immune tolerance during pregnancy. In: Zheng J, editor. Recent advances in research on the human placenta. InTech. p 211-242. doi:10.5772/33541. Available at: http://www.intechopen.com/books/recent-advances-in-research-on-the-human-placenta/mechanisms-of-maternal-immune-tolerance-during-pregnancy. Accessed August 24, 2015; Rijeka, Croatia.
66. Sharpe AH, Freeman GJ. 2002. The B7-CD28 superfamily. Nat Rev Immunol 2:116-126.
67. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, Qiub Y, Jussifa JM, Cartera LL, Wood CR, Chaudhary D. 2004. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 574:37-41.
68. Shinohara T, Taniwaki M, Ishida Y, Kawaichi M, Honjo T. 1994. Structure and chromosomal localization of the human PD-1 gene (PDCD1). Genomics 23:704-706.
69. Tafuri A, Alferink J, Moller P, Gunter J, Hammerling J, Arnold B. 1995. T cell awareness of paternal alloantigens druing pregnancy. Science 270:630-633.
70. Taglauer ES, Yankee TM, Petroff MG. 2009. Maternal PD-1 regulates accumulation of fetal antigen-specific CD8+ T cells in pregnancy. J Reprod Immunol 80:12-21.
71. Tilburgs T, Scherjon SA, Claas FHJ. 2010. Major histocompatibility complex (MHC)-mediated immune regulation of decidual leukocytes at the fetal-maternal interface. J Reprod Immunol 85:58-62.
72. Topalian S, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Poderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M. 2012. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443-2454.
73. Tsushima F, Tanaka K, Otsuki N, Youngnak P, Iwai H, Omura K, Azuma M. 2006. Predominant expression of B7-H1 and its immunoregulatory roles in oral squamous cell carcinoma. Oral Oncol 42:268-274.
74. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. 2014. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568-571.
75. Vacchio MS, Hodes RJ. 2005. Fetal expression of Fas ligand is necessary and sufficient for induction of CD8 T cell tolerance to the fetal antigen H-Y during pregnancy. J Immunol 174:4657-4661.
76. Vibhakar R, Juan G, Traganos F, Darzynkiewicz Z, Finger LR. 1997. Activation induced expression of human programmed death-1 gene in T-lymphocytes. Exp Cell Res 232:25-28.
77. Wafula PO, Teles A, Schumacher A, Pohl K, Yagita H, Volk H-D, Zenclussen AC. 2009. PD-1 but not CTLA-4 blockage abrogates the protective effect of regulatory T cells in a pregnancy murine model. Am J Reprod Immunol 62:283-292.
78. Wang S-C, Li Y-H, Piao H-L, Hong X-W, Zhang D, Xu Y-Y, Tao Y, Wang Y, Yuan M-M, Li D-J, Du M-R. 2015. PD-1 and Tim-3 pathways are associated with regulatory CD8+ T-cell function in decidua and maintenance of normal pregnancy. Cell Death Dis 6:e1738; doi:10.1038/cddis.2015.112
79. Wegmann TG, Lin H, Guilbert LG, Mosmann TR. 1993. Bidirectional cytikine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 14:353-356.
80. Weinbauer GF, Fuchs A, Niehaus M, Luetjens CM. 2011. The enhanced pre- and postnatal study for nonhuman primates: update and perspectives. Birth Defects Res C 93:324-333.
81. Xu C, Mao D, Holers VM, Palanca B, Cheng AM, Molina H. 2000. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science 287:498-501.
82. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G. 2003. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Eng J Med 348:203-213.
83. Zenclussen AC, Gerlof K, Zenclussen ML, Sollwedel A, Bertoja AZ, Ritter T, Kotsch K, Leber J, Volk H-D. 2005. Abnormal T-cell reactivity against paternal antigens in spontaneous abortion. Adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol 166:811-822.